Seeking Alpha

Ampio Pharmaceuticals (AMPE) +7% after its Optima treatment for diabetes-related vision problems...

Ampio Pharmaceuticals (AMPE) +7% after its Optima treatment for diabetes-related vision problems produced "encouraging" results in phase II testing. Ampio plans to discuss the next trial with the FDA at the end of the month. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|